Drug Approval | November 02, 2024
USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Strengthening focus in Alzheimer's disease and neuroscience pipeline
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated
